Table 1 Schistosomiasis candidate vaccines in human clinical trials
From: Schistosomiasis vaccine development: update on human clinical trials
Candidate Vaccine | Species targeted | Clinical Phase | Efficacy in humans and/or animal models | Sponsor |
|---|---|---|---|---|
Recombinant Sh28GST/Alhydrogel® (Bilharvax) | Schistosoma haematobium | Phases 1, 2 & 3 completed | No protection in immunized humans. No effect on worm burden in immunized monkeys but 50% reduction in tissue egg load and up 77% reduction in excreted eggs | University Hospital, Lille & Institut National de la Santé Et de la Recherche Médicale |
Recombinant Sm14/GLA-SE | Schistosoma mansoni | Phases 1 & 2a completed. Phase 2b initiated | 67 and 93% worm reduction in immunized mice and rabbits respectively. | Oswald Cruz Foundation |
Recombinant Sm-TSP-2/ Alhydrogel® | Schistosoma mansoni | Phase 1a completed. Phase 1b initiated | Immunized mice had 57 and 64% reduction in worm and liver egg burden respectively | Baylor College of Medicine |
Recombinant Sm-p80/GLA-SE | Schistosoma mansoni | Phase 1 initiated | 93% reduction in adult female worms in immunized baboons. 90% reduction in tissue egg load and 81% reduction in egg hatching rate | Texas Tech University Health Sciences Center |